The frontline combination of zanidatamab-hrii (Ziihera) and chemotherapy with or without tislelizumab (Tevimbra) was ...

A few years ago, I had a patient who affectionately went by the name “Pops.” At 85 years young, he was full of life and juggling multiple health issues alongside prostate cancer, yet determined not to ...

When we examine vicarious trauma in Latino and other communities of color, we cannot separate individual experience from the ...

Welcome to Onc Nurse On Call, the new podcast from Oncology Nursing News, hosted by editors-in-chief Patricia Jakel, MN, RN, ...

Deborah (Debi) A. Boyle MSN, RN, AOCNS, FAAN, is editor in chief of Oncology Nursing News®. She is a long tenured oncology clinical nurse specialist who has practiced in both Comprehensive Cancer ...

Look back at the top 5 updates for oncology nurses and advanced practices providers published in 2025. From clinical updates ...

The APP ordered a bilateral diagnostic mammogram and left breast ultrasound that revealed extremely dense breast tissue, a right breast simple cyst, and a left breast indeterminate, oval, hypoechoic 1 ...

Melinda Mayorga, RN, MSN, CNS, AGCNS-BC, OCN, is a clinical nurse specialist at Norris Comprehensive Cancer Center University of Southern California in Los Angeles. Melinda Mayorga, RN, MSN, CNS, ...

The FDA has approved the use of subcutaneous amivantamab and hyaluronidase-lpuj across all amivantamab indications. The FDA has approved the use of subcutaneous amivantamab and hyaluronidase-lpuj ...

Frontline maintenance tucatinib plus trastuzumab and pertuzumab increased progression-free survival in patient with HER2-positive metastatic breast cancer. The PFS benefit with tucatinib also extended ...

The treatment combination of T-DXd and pertuzumab was granted FDA approval in the first-line for unresectable or metastatic HER2-positive breast cancer. The FDA has approved fam-trastuzumab deruxtecan ...